<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Vasc Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ann Vasc Dis</journal-id><journal-id journal-id-type="pmc-domain-id">1829</journal-id><journal-id journal-id-type="pmc-domain">avd</journal-id><journal-title-group><journal-title>Annals of Vascular Diseases</journal-title></journal-title-group><issn pub-type="ppub">1881-641X</issn><issn pub-type="epub">1881-6428</issn><publisher><publisher-name>Editorial Committee of Annals of Vascular Diseases</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11196169</article-id><article-id pub-id-type="pmcid-ver">PMC11196169.1</article-id><article-id pub-id-type="pmcaid">11196169</article-id><article-id pub-id-type="pmcaiid">11196169</article-id><article-id pub-id-type="pmid">38919321</article-id><article-id pub-id-type="doi">10.3400/avd.oa.23-00079</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Eicosapentaenoic Acid Level Predicts Long-Term Survival and Cardiovascular or Limb Event in Peripheral Arterial Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7551-3279</contrib-id><name name-style="western"><surname>Kumakura</surname><given-names initials="H">Hisao</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="corr1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Funada</surname><given-names initials="R">Ryuichi</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Matsuo</surname><given-names initials="Y">Yae</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names initials="T">Toshiya</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nakashima</surname><given-names initials="K">Kuniki</given-names></name><degrees>MD, PhD</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsuboi</surname><given-names initials="E">Eitoshi</given-names></name><degrees>MD, PhD</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ichikawa</surname><given-names initials="S">Shuichi</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label>Department of Cardiovascular Medicine, Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital), Shibukawa, Gunma, Japan</aff><aff id="aff2"><label>2</label>Department of Cardiovascular Surgery, Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital), Shibukawa, Gunma, Japan</aff></contrib-group><author-notes><corresp id="corr1"><label>*</label>Corresponding author: Hisao Kumakura, MD, PhD. Department of Cardiovascular Medicine, Kitakanto Cardiovascular Hospital, Shimohakoda 740, Hokkitu-machi, Shibukawa, Gunma 377-0061, Japan Tel: <phone>+81-27-232-7111</phone> E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:kumakura@r.sannet.ne.jp">kumakura@r.sannet.ne.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="ppub"><day>25</day><month>6</month><year>2024</year></pub-date><volume>17</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">465341</issue-id><fpage>135</fpage><lpage>141</lpage><history><date date-type="received"><day>8</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>8</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>25</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-26 17:25:12.857"><day>26</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>@ 2024 The Editorial Committee of Annals of Vascular Diseases.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Editorial Committee of Annals of Vascular Diseases. This work is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike International license.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/2.5/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided the credit of the original work, a link to the license, and indication of any change are properly given, and the original work is not used for commercial purposes. Remixed or transformed contributions must be distributed under the same license as the original.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="avd-17-135.pdf"/><abstract><p><bold>Objectives:</bold> We examined the relationship between plasma eicosapentaenoic acid (EPA) level and long-term all-cause death (ACD) and cardiovascular or limb events in patients with peripheral arterial disease (PAD).</p><p><bold>Method:</bold> We performed a prospective cohort study on 637 PAD patients. The endpoints were ACD, major adverse cardiovascular events (MACEs), and lower extremity arterial events (LEAEs).</p><p><bold>Results:</bold> The incidences of ACD, MACEs, and LEAEs had correlation with EPA levels (p &lt;0.05). Plasma EPA level had significant positive correlations with high-density lipoprotein cholesterol, triglyceride, and estimated glomerular filtration rate (eGFR), and negative correlation with C-reactive protein (CRP). In Cox stepwise multivariate analysis, lower EPA (hazard ratio [HR]: 0.996, 95% confidence interval [CI]: 0.993&#8211;1.000, p = 0.034), ankle brachial pressure index (ABI), body mass index, serum albumin, eGFR, age, CRP, D-dimer, critical limb ischemia, diabetes, cerebrovascular disease (CVD), and statin were related to ACD (p &lt;0.05); lower EPA (HR: 0.997, 95% CI: 0.994&#8211;1.000, p = 0.038), ABI, serum albumin, eGFR, age, diabetes, coronary heart disease, CVD, and statin were related to MACEs (p &lt;0.05); and lower EPA (HR: 0.988, 95% CI: 0.982&#8211;0.993, p &lt;0.001), ABI, and low-density lipoprotein cholesterol were related to LEAEs (p &lt;0.05).</p><p><bold>Conclusions:</bold> Low plasma EPA level was a significant risk factor for ACD, MACEs, and LEAEs in patients with PAD.</p></abstract><kwd-group><kwd>eicosapentaenoic acid</kwd><kwd>limb events</kwd><kwd>all-cause mortality</kwd><kwd>major adverse cardiovascular event</kwd><kwd>peripheral arterial disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>The &#969;-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have significant anti-inflammatory and anti-atherosclerotic actions.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R2" ref-type="bibr"><sup>2)</sup></xref> The Japan EPA lipid intervention study (JELIS) trial has reported the preventive effects of EPA on coronary heart disease (CHD), and EPA aids in reducing the levels of triglyceride in patients with hypercholesterolemia.<xref rid="R3" ref-type="bibr"><sup>3)</sup></xref> Furthermore, PUFAs play an important role in resolving inflammation as results of reducing inflammation markers such as interleukin-6, tumor necrosis factor-alpha (TNF-&#945;), and interleukin-1&#946;.<xref rid="R4" ref-type="bibr"><sup>4)</sup></xref> TNF-&#945; relates to peripheral arterial restenosis, cardiovascular dysfunction, and cardiovascular events.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="R6" ref-type="bibr"><sup>6)</sup></xref></p><p>The subanalysis of the JELIS trial has showed that EPA reduced the incidence of recurrent cerebrovascular disease (CVD).<xref rid="R7" ref-type="bibr"><sup>7)</sup></xref> Moreover, the incidence of CHD is also reduced in patients with peripheral arterial disease (PAD).<xref rid="R8" ref-type="bibr"><sup>8)</sup></xref> Patients with PAD have severe atherosclerosis that causes poor prognosis due to CHD and CVD.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R10" ref-type="bibr"><sup>10)</sup></xref> PAD patients were more likely to have low basal EPA and DHA levels or EPA/arachidonic acid (AA) ratio.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="R12" ref-type="bibr"><sup>12)</sup></xref> Several studies have reported that low EPA level and EPA/AA ratio are atherosclerotic biomarkers reflecting the risk of limb events in PAD patients in small numbers and/or retrospective studies.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref><sup>&#8211;</sup><xref rid="R15" ref-type="bibr"><sup>15</sup></xref>)</p><p>However, long-term pure limb events and cardiovascular or cerebrovascular events associated with basal plasma EPA levels have not been investigated in prospective study in patients with PAD. Moreover, long-term all-cause mortality based on plasma EPA levels has not been examined in patients with PAD. Therefore, the aim of the current study was to assess these outcomes for 15 years associated with basal plasma EPA levels in patients with PAD.</p></sec><sec sec-type="patients|methods" id="s2"><title>Patients and Methods</title><sec id="s2_1"><title>Patients</title><p>The subjects were Japanese patients with PAD who were referred to the Cardiovascular Hospital of Central Japan in the period from March 1, 2002 to January 31, 2023. The methods and design of the prospective study were conducted in accordance with the Declaration of Helsinki, and the protocol used in this research was approved by the Medical Ethics Committee in our institution (CCJ-EA-006). Patients who gave written informed consent to participation in the study and met the following inclusion criteria were selected: (1) ankle brachial pressure index (ABI) &lt;0.90; (2) clinical symptoms (critical limb ischemia [CLI] or intermittent claudication); and (3) a stenotic lesion of &#8805;70% in the femoropopliteal or iliac artery on ultrasound or angiography. Patients with peripheral lesions owing to non-atherosclerotic causes were excluded. Patients treated with EPA curatives or ingested dietary EPA-rich supplements at baseline and during follow-up period were excluded. Patients with dementia were also excluded on account of the difficulty in checking medical status and vital signs.</p></sec><sec id="s2_2"><title>Baseline clinical characteristics</title><p>Age, ABI, body mass index (BMI), and smoking history status were obtained for each patient. A morning blood sample was collected to determine the levels of albumin, glucose, creatinine, triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), and D-dimer. Moreover, we collected a methylated blood sample for PUFAs measure. The measurements of serum EPA, DHA, and AA were performed using a Shimadzu GC-2010 gas chromatograph (Shimadzu Corporation, Kyoto, Japan). Diabetes mellitus (DM) was specified as a fasting plasma glucose level &gt;126 mg/dL in at least two measurements or receiving antidiabetes therapy. Hypertension was defined as required antihypertensive oral therapy or blood pressure &#8805;140/90 mmHg recorded at least twice.</p></sec><sec id="s2_3"><title>Data analysis and endpoints</title><p>Each subject was followed up at 2-, 4-, or 6-month intervals after treatment. Medical status and vital signs were assessed using hospital data and written questionnaires on life status monitored by the Foot Care Club.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="R16" ref-type="bibr"><sup>16)</sup></xref> Ischemic cerebral infarction was determined as the presence of a new focal neurological deficit, with brain computed tomography or magnetic resonance imaging to determine the focal lesions. Transient ischemic attack (TIA) was defined as the presence of a new neurological symptom lasting &lt;24 h. The diagnosis of myocardial infarction was that used previously.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R17" ref-type="bibr"><sup>17)</sup></xref> Limb events during follow-up were defined as the progression of a new stenosis or restenosis identified as a decrease in ABI of &#8805;0.15 and &#8805;50% stenosis on duplex ultrasonography or angiography in the lower extremity arterial lesions and above-the-ankle amputation.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R18" ref-type="bibr"><sup>18)</sup></xref></p><p>The endpoints were all-cause death (ACD), major adverse cardiovascular events (MACEs: ACD, TIA, non-fatal CVD, or non-fatal myocardial infarction), and lower extremity arterial events (LEAEs: repeat revascularization for a lower extremity artery, occurrence of a new lower extremity lesion, or major amputation).</p></sec><sec id="s2_4"><title>Statistical analysis</title><p>IBM SPSS Statistics ver. 25.0 (IBM Corp, Armonk, NY, USA) was utilized for all statistical analyses. Categorical variables are expressed as a number (%) and were compared via chi-square test. Continuous variables are shown as a median (interquartile range) and were evaluated with the Mann&#8211;Whitney U test. In multiple regression analysis, all risk factors were first examined with simple Pearson correlations. Factors with p &lt;0.05 in this correlation analysis were used in stepwise forward multiple regression analysis to define relationships between EPA level and individual risk factors. Kaplan&#8211;Meier analysis was used to evaluate ACD, MACEs, and LEAEs with comparison by the log-rank test. In the Cox multivariate regression model, hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by means of forward stepwise regression analyses with Wald statistic to define significant factors associated with endpoints. The Cox univariate regression model was used for individual factors to search for affecting factors for endpoints. A p &lt;0.05 was determined as statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Patient characteristics and causes of death</title><p>Among 658 subjects, follow-up was possible for 637 patients, and the median and mean ages were 73 (67&#8211;80) and 72.8 &#177; 10.3 years. The median follow-up periods were 71 (34&#8211;126) months. There were 235 deaths (36.9%) during the follow-up period. The cumulative 5-, 10-, and 15-year freedom from ACD in all patients were 79.6%, 60.4%, and 47.7%, respectively. The prevalence of cardiovascular-related death was 53.2% (n = 125), as cardiac or major vascular disease (n = 103, 43.8%) and CVD (n = 22, 9.4%). Other causes of deaths were malignancy (n = 53, 22.6%), pneumonia (n = 34, 14.5%), and other causes (n = 23, 9.8%).</p><p>The median and mean EPA levels were 50.9 (32.4&#8211;80.0) and 62.6 &#177; 44.8 &#956;g/mL. Following these results, the patients were divided into two groups based on plasma EPA levels with median: E1: &#8804;50.9 &#956;g/mL (n = 319) and E2: &#8805;51.0 &#956;g/mL (n = 318). The comorbidities and clinical characteristics in PAD patients divided by median are shown in <xref rid="table-1" ref-type="table"><bold>Table 1</bold></xref>.</p><table-wrap position="float" id="table-1" orientation="portrait"><label/><caption><title>Table&#8194;1&#8195;Characteristics of subjects in all patients, E1, and E2 based on EPA levels</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1"/><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">All Patients<break/>(n = 637)</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">E1<break/>EPA &#8804; 50.9 &#956;g/mL<break/>(n = 319) (50.1%)</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">E2<break/>EPA &#8805; 51.0 &#956;g/mL<break/>(n = 318) (49.9%)</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Age (year)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">73 (67&#8211;80)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">73 (66&#8211;81)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">74 (67&#8211;80)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.575</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Male sex</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">464 (72.8%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">231 (72.4%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">233 (73.3%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.859</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">ABI</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.71 (0.55&#8211;0.86)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.70 (0.50&#8211;0.84)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.72 (0.58&#8211;0.87)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.015</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Intermittent claudication</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">543 (85.2%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">263 (82.4%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">280 (88.1%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.057</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Critical limb ischemia</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">94 (14.8%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">56 (17.6%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">38 (11.9%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.057</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">22.4 (20.3&#8211;24.5)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">21.8 (19.6&#8211;24.4)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">22.7 (20.9&#8211;24.6)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.002</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Coronary heart disease</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">229 (35.9%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">121 (37.9%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">108 (34.0%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.322</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">History of stroke or TIA</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">97 (15.2%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">52 (16.3%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">45 (14.2%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.508</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Diabetes mellitus</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">287 (45.1%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">147 (46.1%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">140 (44.0%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.633</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Hypertension</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">457 (71.7%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">230 (72.1%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">227 (71.4%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.861</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Smoking</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">478 (75.0%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">241 (75.5%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">237 (74.5%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.784</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Medications</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Aspirin</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">420 (65.9%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">205 (64.3%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">215 (67.6%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.372</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Thienopyridines</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">268 (42.1%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">132 (41.3%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">136 (42.8%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.723</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Cilostazol</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">93 (14.6%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">46 (14.4%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">47 (14.8%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.911</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Beraprost</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">202 (31.7%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">108 (33.9%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">94 (29.6%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.709</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;ARB</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">263 (41.3%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">131 (41.4%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">132 (41.5%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.936</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Ca antagonist</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">342 (53.7%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">170 (53.3%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">172 (54.1%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.874</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;&#946;-blocker</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">103 (16.2%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">62 (19.4%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">41 (12.9%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.031</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Statin</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">467 (73.3%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">238 (74.6%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">229 (72.0%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.459</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Revascularization</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">342 (53.8%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">152 (47.8%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">190 (59.7%)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.003</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Basic metabolic panel</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1"/></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;EPA (&#956;g/mL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">50.9 (32.4&#8211;80.0)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">32.4 (22.9&#8211;40.6)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">80.7 (63.3&#8211;110.5)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;AA (&#181;g/mL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">144.7 (115.7&#8211;177.9)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">137.5 (109.6&#8211;170.4)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">150.5 (125.6&#8211;186.0)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;DHA (&#181;g/mL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">114.7 (85.0&#8211;158.9)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">92.4 (72.5&#8211;115.0)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">151.5 (114.5&#8211;195.1)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;EPA/AA ratio</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.35 (0.22&#8211;0.55)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.23 (0.16&#8211;0.31)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.55 (0.40&#8211;0.80)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Serum albumin (g/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">4.0 (3.7&#8211;4.3)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">3.9 (3.7&#8211;4.2)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">4.1 (3.9&#8211;4.3)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;CRP (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.15 (0.07&#8211;0.39)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.17 (0.08&#8211;0.47)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.14 (0.07&#8211;0.33)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.134</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;D-dimer (&#181;g/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.8 (0.5&#8211;1.7)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">1.0 (0.5&#8211;2.3)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.7 (0.5&#8211;1.2)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;eGFR (mL/min/1.73 m<sup>2</sup>)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">59.4 (44.1&#8211;72.0)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">57.6 (38.1&#8211;71.0)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">60.5 (49.1&#8211;73.1)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Total cholesterol (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">191 (163&#8211;218)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">184 (157&#8211;210)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">197 (172&#8211;226)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;Triglyceride (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">136 (99&#8211;191)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">126 (95&#8211;177)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">147 (102&#8211;195)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.005</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;HDL-C (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">50 (42&#8211;52)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">49 (41&#8211;58)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">52 (44&#8211;65)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.005</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">&#8195;LDL-C (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">113 (90&#8211;133)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">110 (86&#8211;94)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">117 (94&#8211;140)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="table-1fn1"><p>EPA: eicosapentaenoic acid; ABI: ankle brachial pressure index; TIA: transient ischemic attack; ARB: angiotensin receptor blocker; AA: arachidonic acid; DHA: docosahexaenoic acid; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol</p></fn></table-wrap-foot></table-wrap><p>Patients in the E1 category had lower ABI, BMI, serum albumin, estimated glomerular filtration rate (eGFR), levels of total cholesterol, triglyceride, LDL-C, HDL-C, AA, DHA, EPA/AA ratio, and higher D-dimer. The prevalence of revascularization was lower, and treatment with &#946;-blocker was higher in the E1 category.</p></sec><sec id="s3_2"><title>Correlational statistics among EPA and cardiovascular risk factors</title><p>Plasma EPA level had significant positive correlations with ABI, serum albumin, eGFR, total cholesterol, triglyceride, and HDL-C, and negative correlations with CLI, CRP, D-dimer, and CHD in simple Pearson correlation analysis (p &lt;0.05). Within PUFAs, plasma EPA level had significant positive correlations with DHA level and EPA/AA ratio in simple Pearson correlation analysis (p &lt;0.01). The plasma EPA levels had significant positive correlations with HDL-C, triglyceride, and eGFR, and negative correlation with CRP in correlational statistics among these significant factors with stepwise forward multiple regression analysis (p &lt;0.05, <xref rid="table-2" ref-type="table"><bold>Table 2</bold></xref>).</p><table-wrap position="float" id="table-2" orientation="portrait"><label/><caption><title>Table&#8194;2&#8195;Correlational statistics between eicosapentaenoic acid level and other risk factors</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">Factor</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">&#946;</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">B</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">95% CI</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">HDL-C (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.152</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.431</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.197 to 0.665</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">Triglyceride (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.131</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.057</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.021 to 0.092</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.002</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">C-reactive protein (mg/dL)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&#8211;0.098</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&#8211;3.395</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">&#8211;6.111 to &#8211;0.679</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.014</td></tr><tr><td style="text-align: left; vertical-align: middle;" rowspan="1" colspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.102</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.180</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.040 to 0.319</td><td style="text-align: center; vertical-align: middle;" rowspan="1" colspan="1">0.012</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="table-2fn1"><p>R<sup>2</sup> = 0.058, F for change in R<sup>2</sup> = 9.334, p &lt;0.001. &#946;: standardized coefficient; B: non-standardized coefficient; CI: confidence interval for B; HDL-C: high-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_3"><title>Factors for ACD, MACEs, and LEAEs</title><p>The 15-year cumulative rates for freedom from ACD are indicated in <xref rid="figure1" ref-type="fig"><bold>Fig. 1A</bold></xref>. There was significant difference between E1 and E2 (p = 0.003). In Cox forward stepwise regression analysis, age, CRP, D-dimer, lower EPA, ABI, BMI, serum albumin, eGFR, CLI, DM, and CVD were related to ACD, and statin treatment decreased ACD (p &lt;0.05, <xref rid="table-3" ref-type="table"><bold>Table 3</bold></xref>).</p><fig position="float" id="figure1" orientation="portrait"><caption><title>Fig.&#8194;1&#8194;(<bold>A</bold>) Freedom from ACD according to EPA levels is demonstrated with significant difference between E1 and E2 (p = 0.003). (<bold>B</bold>) Freedom from MACEs according to EPA levels is demonstrated with significant difference between E1 and E2 (p = 0.001). ACD: all-cause death; EPA: eicosapentaenoic acid; MACEs: major adverse cardiovascular events.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="avd-17-135-g001.jpg"/></fig><table-wrap position="float" id="table-3" orientation="portrait"><label/><caption><title>Table&#8194;3&#8195;Cox stepwise multivariate regression analyses for ACD, MACEs, and LEAEs</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th style="text-align: left; vertical-align: middle" rowspan="3" colspan="1">Factors</th><th style="text-align: center; vertical-align: middle; border-bottom: thin solid" colspan="3" rowspan="1">ACD</th><th style="text-align: center; vertical-align: middle; border-bottom: thin solid" colspan="3" rowspan="1">MACEs</th><th style="text-align: center; vertical-align: middle; border-bottom: thin solid" colspan="3" rowspan="1">LEAEs</th></tr><tr><th style="text-align: center; vertical-align: middle; border-bottom: thin solid" colspan="3" rowspan="1">Multivariate analysis</th><th style="text-align: center; vertical-align: middle; border-bottom: thin solid" colspan="3" rowspan="1">Multivariate analysis</th><th style="text-align: center; vertical-align: middle; border-bottom: thin solid" colspan="3" rowspan="1">Multivariate analysis</th></tr><tr><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">HR</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">95% CI</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">p-value</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">HR</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">95% CI</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">p-value</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">HR</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">95% CI</th><th style="text-align: center; vertical-align: middle" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="left" rowspan="1" colspan="1">1.071</td><td align="left" rowspan="1" colspan="1">1.055&#8211;1.087</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">1.038</td><td align="left" rowspan="1" colspan="1">1.025&#8211;1.051</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ABI</td><td align="left" rowspan="1" colspan="1">0.558</td><td align="left" rowspan="1" colspan="1">0.327&#8211;0.952</td><td align="left" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.565</td><td align="left" rowspan="1" colspan="1">0.368&#8211;0.867</td><td align="left" rowspan="1" colspan="1">0.009</td><td align="left" rowspan="1" colspan="1">0.373</td><td align="left" rowspan="1" colspan="1">0.212&#8211;0.657</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">0.939</td><td align="left" rowspan="1" colspan="1">0.897&#8211;0.983</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Critical limb ischemia</td><td align="left" rowspan="1" colspan="1">1.596</td><td align="left" rowspan="1" colspan="1">1.097&#8211;2.322</td><td align="left" rowspan="1" colspan="1">0.014</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Coronary heart disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.249</td><td align="left" rowspan="1" colspan="1">1.778&#8211;2.845</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">History of stroke or TIA</td><td align="left" rowspan="1" colspan="1">1.478</td><td align="left" rowspan="1" colspan="1">1.052&#8211;2.076</td><td align="left" rowspan="1" colspan="1">0.024</td><td align="left" rowspan="1" colspan="1">1.460</td><td align="left" rowspan="1" colspan="1">1.089&#8211;1.959</td><td align="left" rowspan="1" colspan="1">0.011</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">1.426</td><td align="left" rowspan="1" colspan="1">1.054&#8211;1.929</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">1.403</td><td align="left" rowspan="1" colspan="1">1.114&#8211;1.767</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">EPA (&#956;g/mL)</td><td align="left" rowspan="1" colspan="1">0.996</td><td align="left" rowspan="1" colspan="1">0.993&#8211;1.000</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">0.997</td><td align="left" rowspan="1" colspan="1">0.994&#8211;1.000</td><td align="left" rowspan="1" colspan="1">0.038</td><td align="left" rowspan="1" colspan="1">0.988</td><td align="left" rowspan="1" colspan="1">0.982&#8211;0.993</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum albumin (g/dL)</td><td align="left" rowspan="1" colspan="1">0.435</td><td align="left" rowspan="1" colspan="1">0.321&#8211;0.590</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">0.509</td><td align="left" rowspan="1" colspan="1">0.387&#8211;0.670</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="left" rowspan="1" colspan="1">1.099</td><td align="left" rowspan="1" colspan="1">1.014&#8211;1.192</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">D-dimer (&#181;g/dL)</td><td align="left" rowspan="1" colspan="1">1.054</td><td align="left" rowspan="1" colspan="1">1.030&#8211;1.079</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">0.987</td><td align="left" rowspan="1" colspan="1">0.982&#8211;0.993</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">0.994</td><td align="left" rowspan="1" colspan="1">0.989&#8211;0.999</td><td align="left" rowspan="1" colspan="1">0.017</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDL-C (mg/dL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.005</td><td align="left" rowspan="1" colspan="1">1.001&#8211;1.010</td><td align="left" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">0.486</td><td align="left" rowspan="1" colspan="1">0.367&#8211;0.645</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">0.534</td><td align="left" rowspan="1" colspan="1">0.423&#8211;0.675</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="table-3fn1"><p>HR: hazard ratio; CI: confidence interval; ABI: ankle brachial pressure index; TIA: transient ischemic attack; EPA: eicosapentaenoic acid; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; ACD: all-cause death; MACEs: major adverse cardiovascular events; LEAEs: lower extremity arterial events</p></fn></table-wrap-foot></table-wrap><p>The 15-year cumulative rates for freedom from MACEs are indicated in <xref rid="figure1" ref-type="fig"><bold>Fig. 1B</bold></xref>. There was significant difference between E1 and E2 (p = 0.001). In Cox forward stepwise regression analysis, age, lower EPA, ABI, serum albumin, eGFR, CHD, CVD, and DM were related to MACEs, and statin decreased MACEs (p &lt;0.05, <xref rid="table-3" ref-type="table"><bold>Table 3</bold></xref>).</p><p>The 15-year cumulative rates for freedom from LEAEs are indicated in <xref rid="figure2" ref-type="fig"><bold>Fig. 2</bold></xref>. There was significant difference between E1 and E2 (p &lt;0.001). In Cox forward stepwise regression analysis, lower EPA, ABI, and higher LDL-C were related to LEAEs (p &lt;0.05, <xref rid="table-3" ref-type="table"><bold>Table 3</bold></xref>).</p><fig position="float" id="figure2" orientation="portrait"><caption><title>Fig.&#8194;2&#8194;Freedom from LEAEs according to EPA levels is demonstrated with significant difference between E1 and E2 (p &lt;0.001). LEAEs: lower extremity arterial events; EPA: eicosapentaenoic acid.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="avd-17-135-g002.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This study represented the first prospective clinical results for the relationships between basal plasma EPA level and 15-year ACD, MACEs, and LEAEs in patients with PAD. Compared with low plasma EPA level, patients with high plasma EPA level had significantly low rate in LEAEs during the follow-up period in PAD patients. The cumulative incidences of ACD and MACEs were also significantly increased relative to the lower plasma EPA levels. PUFAs play an important role in resolving inflammation as the result of reducing inflammation markers.<xref rid="R4" ref-type="bibr"><sup>4)</sup></xref> The subanalysis of the JELIS trial has reported that administration of highly purified EPA reduced the incidences of CHD and recurrent stroke in patients with hypercholesterolemia.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="R8" ref-type="bibr"><sup>8)</sup></xref></p><p>In this study, plasma EPA levels had significant positive correlations with HDL-C, triglyceride, and eGFR. High-density lipoprotein is a heterogeneous population of particles, and smaller HDL-C particles are more efficient in cholesterol efflux than large particles in macrophages.<xref rid="R19" ref-type="bibr"><sup>19)</sup></xref> Dense and smaller HDL-C particles have more anti-inflammatory and antioxidant properties reducing LDL-C oxidation in the subendothelial layer of the arterial wall.<xref rid="R20" ref-type="bibr"><sup>20)</sup></xref> PUFAs are effective in the reduction of cardiovascular risk associated with size changes and improvement in HDL-C particles.<xref rid="R21" ref-type="bibr"><sup>21)</sup></xref> In the current study, LDL-C is an independent risk factor for LEAEs. High LDL-C is an independent risk factor for patients with atherosclerotic vascular diseases, and intensive lowering therapy for LDL-C is effective for decreasing cardiovascular events in these patients.<xref rid="R22" ref-type="bibr"><sup>22)</sup></xref></p><p>We have reported obesity paradox and the geriatric nutritional risk index are significant predictors for ACD, MACEs, and MACEs plus limb events (MACLE) in PAD patients.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="R23" ref-type="bibr"><sup>23)</sup></xref> Plasma triglyceride levels have significant positive correlation with BMI.<xref rid="R10" ref-type="bibr"><sup>10)</sup></xref> In this study, lower BMI and serum albumin were related to ACD. Thus, malnutrition based on low BMI or triglyceride and chronic kidney disease are strong risk factors for ACD in patients with cardiovascular disease.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25)</sup></xref> Moreover, increasing levels of PUFAs in membranes affect the uptake and intracellular metabolism of PUFAs in the kidney.<xref rid="R26" ref-type="bibr"><sup>26)</sup></xref> These results suggested that higher triglyceride and eGFR levels might be the causes of higher plasma EPA levels.</p><p>Higher CRP is a significant predictor for ACD, MACEs, and MACLE in PAD patients.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R27" ref-type="bibr"><sup>27)</sup></xref> In the current study, the plasma EPA levels had significant negative correlation with CRP and the higher CRP levels significantly related to ACD. Thus, these inflammations induced by various cytokines affect both atherosclerosis development and cardiovascular remodeling in these subjects.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="R5" ref-type="bibr"><sup>5)</sup></xref></p><p>DHA is one type of PUFAs and improve endothelial dysfunction to increase the expression of endothelial nitric oxide synthase.<xref rid="R2" ref-type="bibr"><sup>2)</sup></xref> In this study, Kaplan&#8211;Meier analysis showed a significant difference only in the LEAEs divided into two groups based on DHA levels with median. Cox univariate analysis showed that DHA was a predictor for LEAEs. In stepwise multivariate analysis, DHA was not a significant predictor for LEAEs. However, DHA was a significant predictor for LEAEs if EPA was excluded from the factors in stepwise multivariate analysis.</p><p>Several studies have reported that high plasma EPA/AA ratio is an atherosclerotic biomarker reflecting the risk of LEAEs and MACEs in patients with PAD.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="R14" ref-type="bibr"><sup>14)</sup></xref> The reduced risks associated with high EPA/AA ratio could be ascribed to either a greater role of EPA in stabilizing atherosclerotic plaque or a smaller role of AA in destabilizing atherosclerotic plaque.<xref rid="R28" ref-type="bibr"><sup>28)</sup></xref> In the current study, Kaplan&#8211;Meier analysis showed significant differences in the LEAEs and MACEs divided into two groups based on EPA/AA ratio with median. However, Cox univariate analysis showed that EPA/AA ratio was a predictor for LEAEs alone. In stepwise multivariate analysis, EPA/AA ratio was not a predictor for LEAEs, suggesting a more meaning role for basal plasma EPA levels.</p><p>The results of <xref rid="table-3" ref-type="table"><bold>Table 3</bold></xref> and Kaplan&#8211;Meier curves in ACD and MACEs were relatively similar, but the result of LEAEs showed a different pattern. In this study, we have changed the outcomes from classical MACLE to LEAEs. In LEAEs, reduplicated cardiovascular events and ACD were removed from the outcome in MACLE, and the effect of EPA and other risk factors for pure leg events was articulated. Moreover, the DHA level and EPA/AA ratio had significant positive correlations with EPA level within PUFAs. As described above, the DHA level and EPA/AA ratio had not significant but similar effects for LEAEs alone. The overlapped effect of these three factors may be another cause of the different patterns in LEAEs compared with ACD or MACEs.</p><p>These results suggested that the administration of highly purified EPA or EPA plus DHA might be effective in reducing the incidence of ACD, MACEs, and LEAEs in PAD patients with low basal plasma EPA levels.</p><sec id="s4_1"><title>Study limitations</title><p>There are several limitations in the current study. First, the study was based on data from a single facility and the number of patients was relatively small. Second, the prevalence of therapy with statins during the follow-up period was relatively low based on the recent guidelines, but the usage has increased over time. Further prospective long-term clinical follow-up data are needed for investigation of outcomes and risk factors with a larger patient cohort in PAD patients.</p></sec></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>Cumulative incidences of ACD, MACEs, and LEAEs had significant correlations with lower plasma EPA levels. Thus, low plasma EPA level was defined as a predictor for 15-year mortality, cardiovascular events, and fate of the limb in patients with PAD.</p></sec><sec sec-type="disclosure|statement" id="s6"><title>Disclosure Statement</title><p>The authors declare no conflict of interest.</p></sec><sec sec-type="auth|contributions" id="s7"><title>Author Contributions</title><p>Study conception: HK and SI</p><p>Data collection: RF, YM, TI, KN, and ET</p><p>Analysis: HK and RF</p><p>Investigation: HK, RF, and SI</p><p>Writing: HK and SI</p><p>Funding acquisition: None</p><p>Critical review and revision: all authors</p><p>Final approval of the article: all authors</p><p>Accountability for all aspects of the work: all authors.</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1)</label><mixed-citation publication-type="journal">Das UN. <article-title>Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules</article-title>. <source>Lipids Health Dis</source><year>2008</year>; <volume>7</volume>: <fpage>37</fpage>.<pub-id pub-id-type="pmid">18922179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1476-511X-7-37</pub-id><pub-id pub-id-type="pmcid">PMC2576273</pub-id></mixed-citation></ref><ref id="R2"><label>2)</label><mixed-citation publication-type="journal">Stebbins CL, Stice JP, Hart CM, et al. <article-title>Effects of dietary decosahexaenoic acid (DHA) on eNOS in human coronary artery endothelial cells</article-title>. <source>J Cardiovasc Pharmacol Ther</source><year>2008</year>; <volume>13</volume>: <fpage>261</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18682551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1074248408322470</pub-id><pub-id pub-id-type="pmcid">PMC4437661</pub-id></mixed-citation></ref><ref id="R3"><label>3)</label><mixed-citation publication-type="journal">Yokoyama M, Origasa H, Matsuzaki M, et al. <article-title>Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis</article-title>. <source>Lancet</source><year>2007</year>; <volume>369</volume>: <fpage>1090</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17398308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(07)60527-3</pub-id></mixed-citation></ref><ref id="R4"><label>4)</label><mixed-citation publication-type="journal">Ishihara T, Yoshida M, Arita M. <article-title>Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis</article-title>. <source>Int Immunol</source><year>2019</year>; <volume>31</volume>: <fpage>559</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">30772915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxz001</pub-id></mixed-citation></ref><ref id="R5"><label>5)</label><mixed-citation publication-type="journal">Rordorf R, Savastano S, Sanzo A, et al. <article-title>Tumor necrosis factor-a predicts response to cardiac resynchronization therapy in patients with chronic heart failure</article-title>. <source>Circ J</source><year>2014</year>; <volume>78</volume>: <fpage>2232</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24954238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.cj-14-0023</pub-id></mixed-citation></ref><ref id="R6"><label>6)</label><mixed-citation publication-type="journal">Spychalska-Zwoli&#324;ska M, Anaszewicz M, Wisniewska J, et al. <article-title>Blood adipocytokine concentration in patients with peripheral artery disease</article-title>. <source>Int Angiol</source><year>2020</year>; <volume>39</volume>: <fpage>500</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">33086778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23736/S0392-9590.20.04479-X</pub-id></mixed-citation></ref><ref id="R7"><label>7)</label><mixed-citation publication-type="journal">Tanaka K, Ishikawa Y, Yokoyama M, et al. <article-title>Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial</article-title>. <source>Stroke</source><year>2008</year>; <volume>39</volume>: <fpage>2052</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18451347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.107.509455</pub-id></mixed-citation></ref><ref id="R8"><label>8)</label><mixed-citation publication-type="journal">Ishikawa Y, Yokoyama M, Saito Y, et al. <article-title>Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease</article-title>. <source>Circ J</source><year>2010</year>; <volume>74</volume>: <fpage>1451</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20484828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.cj-09-0520</pub-id></mixed-citation></ref><ref id="R9"><label>9)</label><mixed-citation publication-type="journal">Norgren L, Hiatt WR, Dormandy JA, et al. <article-title>Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)</article-title>. <source>J Vasc Surg</source><year>2007</year>; <volume>45 Suppl S</volume>: <fpage>S5</fpage>&#8211;<lpage>S67.</lpage><pub-id pub-id-type="pmid">17223489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2006.12.037</pub-id></mixed-citation></ref><ref id="R10"><label>10)</label><mixed-citation publication-type="journal">Kumakura H, Kanai H, Aizaki M, et al. <article-title>The influence of the obesity paradox and chronic kidney disease on long-term survival in a Japanese cohort with peripheral arterial disease</article-title>. <source>J Vasc Surg</source><year>2010</year>; <volume>52</volume>: <fpage>110</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20478682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2010.02.008</pub-id></mixed-citation></ref><ref id="R11"><label>11)</label><mixed-citation publication-type="journal">Fukuda S, Fujioka S, Hosaka S, et al. <article-title>Relationship between arteriosclerosis obliterans and the ratio of serum eicosapentaenoic acid to arachidonic acid</article-title>. <source>Ann Thorac Cardiovasc Surg</source><year>2014</year>; <volume>20</volume>: <fpage>44</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23364231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5761/atcs.oa.12.02063</pub-id></mixed-citation></ref><ref id="R12"><label>12)</label><mixed-citation publication-type="journal">Gautam M, Izawa A, Shiba Y, et al. <article-title>Importance of fatty acid compositions in patients with peripheral arterial disease</article-title>. <source>PLoS One</source><year>2014</year>; <volume>9</volume>: <fpage>e107003</fpage>.<pub-id pub-id-type="pmid">25191963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0107003</pub-id><pub-id pub-id-type="pmcid">PMC4156400</pub-id></mixed-citation></ref><ref id="R13"><label>13)</label><mixed-citation publication-type="journal">Hishikari K, Kimura S, Yamakami Y, et al. <article-title>The prognostic value of the serum eicosapentaenoic acid to arachidonic acid ratio in relation to clinical outcomes after endovascular therapy in patients with peripheral artery disease caused by femoropopliteal artery lesions</article-title>. <source>Atherosclerosis</source><year>2015</year>; <volume>239</volume>: <fpage>583</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25733330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2015.02.035</pub-id></mixed-citation></ref><ref id="R14"><label>14)</label><mixed-citation publication-type="journal">Ito N, Hishikari K, Abe F, et al. <article-title>Eicosapentaenoic acid levels predict prognosis of peripheral artery disease caused by aortoiliac artery lesions</article-title>. <source>Nutr Metab Cardiovasc Dis</source><year>2021</year>; <volume>31</volume>: <fpage>263</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">33500105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.numecd.2020.08.030</pub-id></mixed-citation></ref><ref id="R15"><label>15)</label><mixed-citation publication-type="journal">Nishibe T, Dardik A, Nishibe M, et al. <article-title>Relationship between serum eicosapentaenoic acid to arachidonic acid ratio and atherosclerotic risk factors in patients with peripheral artery disease</article-title>. <source>Vasc Endovascular Surg</source><year>2021</year>; <volume>55</volume>: <fpage>112</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">33073735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1538574420967130</pub-id></mixed-citation></ref><ref id="R16"><label>16)</label><mixed-citation publication-type="journal">Kumakura H, Kanai H, Araki Y, et al. <article-title>15-year patency and life expectancy after primary stenting guided by intravascular ultrasound for iliac artery lesions in peripheral arterial disease</article-title>. <source>JACC Cardiovasc Interv</source><year>2015</year>; <volume>8</volume>: <fpage>1893</fpage>&#8211;<lpage>901</lpage>.<pub-id pub-id-type="pmid">26604061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcin.2015.08.020</pub-id></mixed-citation></ref><ref id="R17"><label>17)</label><mixed-citation publication-type="journal">Thygesen K, Alpert JS, Jaffe AS, et al. <article-title>Third universal definition of myocardial infarction</article-title>. <source>Circulation</source><year>2012</year>; <volume>126</volume>: <fpage>2020</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">22923432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0b013e31826e1058</pub-id></mixed-citation></ref><ref id="R18"><label>18)</label><mixed-citation publication-type="journal">Ranke C, Creutzig A, Alexander K. <article-title>Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction</article-title>. <source>Ultrasound Med Biol</source><year>1992</year>; <volume>18</volume>: <fpage>433</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">1509618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0301-5629(92)90082-l</pub-id></mixed-citation></ref><ref id="R19"><label>19)</label><mixed-citation publication-type="journal">Du XM, Kim MJ, Hou L, et al. <article-title>HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export</article-title>. <source>Circ Res</source><year>2015</year>; <volume>116</volume>: <fpage>1133</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">25589556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.116.305485</pub-id></mixed-citation></ref><ref id="R20"><label>20)</label><mixed-citation publication-type="journal">Kontush A, Chapman MJ. <article-title>Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities</article-title>. <source>Curr Opin Lipidol</source><year>2010</year>; <volume>21</volume>: <fpage>312</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20581677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOL.0b013e32833bcdc1</pub-id></mixed-citation></ref><ref id="R21"><label>21)</label><mixed-citation publication-type="journal">Cartolano FC, Dias GD, Miyamoto S, et al. <article-title>Omega-3 fatty acids improve functionality of high-density lipoprotein in individuals with high cardiovascular risk: a randomized, parallel, controlled and double-blind clinical trial</article-title>. <source>Front Nutr</source><year>2022</year>; <volume>8</volume>: <fpage>767535</fpage>.<pub-id pub-id-type="pmid">35281761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnut.2021.767535</pub-id><pub-id pub-id-type="pmcid">PMC8905646</pub-id></mixed-citation></ref><ref id="R22"><label>22)</label><mixed-citation publication-type="journal">Alkhalil M, Kuzemczak M, Whitehead N, et al. <article-title>Meta-analysis of intensive lipid-lowering therapy in patients with polyvascular disease</article-title>. <source>J Am Heart Assoc</source><year>2021</year>; <volume>10</volume>: <fpage>e017948</fpage>.<pub-id pub-id-type="pmid">33586467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.120.017948</pub-id><pub-id pub-id-type="pmcid">PMC8174253</pub-id></mixed-citation></ref><ref id="R23"><label>23)</label><mixed-citation publication-type="journal">Matsuo Y, Kumakura H, Kanai H, et al. <article-title>The geriatric nutritional risk index predicts long-term survival and cardiovascular or limb events in peripheral arterial disease</article-title>. <source>J Atheroscler Thromb</source><year>2020</year>; <volume>27</volume>: <fpage>134</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">31217396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5551/jat.49767</pub-id><pub-id pub-id-type="pmcid">PMC7049470</pub-id></mixed-citation></ref><ref id="R24"><label>24)</label><mixed-citation publication-type="journal">Davenport DL, Xenos ES, Hosokawa P, et al. <article-title>The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality</article-title>. <source>J Vasc Surg</source><year>2009</year>; <volume>49</volume>: <fpage>140</fpage>&#8211;<lpage>7</lpage>, <comment>147.e1; discussion, 147</comment>.<pub-id pub-id-type="pmid">19028047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2008.08.052</pub-id></mixed-citation></ref><ref id="R25"><label>25)</label><mixed-citation publication-type="journal">Sarnak MJ, Levey AS, Schoolwerth AC, et al. <article-title>Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research</article-title>, <source>Clinical Cardiology, and Epidemiology and Prevention. Circulation</source><year>2003</year>; <volume>108</volume>: <fpage>2154</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">14581387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.CIR.0000095676.90936.80</pub-id></mixed-citation></ref><ref id="R26"><label>26)</label><mixed-citation publication-type="journal">Hagve TA, Woldseth B, Brox J, et al. <article-title>Membrane fluidity and fatty acid metabolism in kidney cells from rats fed purified eicosapentaenoic acid or purified docosahexaenoic acid</article-title>. <source>Scand J Clin Lab Invest</source><year>1998</year>; <volume>58</volume>: <fpage>187</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">9670342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00365519850186571</pub-id></mixed-citation></ref><ref id="R27"><label>27)</label><mixed-citation publication-type="journal">Kumakura H, Kanai H, Hojo Y, et al. <article-title>Long-term survival and fate of the leg in de novo intermittent claudication</article-title>. <source>Eur Heart J Qual Care Clin Outcomes</source><year>2017</year>; <volume>3</volume>: <fpage>208</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">28838085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ehjqcco/qcw057</pub-id></mixed-citation></ref><ref id="R28"><label>28)</label><mixed-citation publication-type="journal">Simopoulos AP. <article-title>The importance of the ratio of omega-6/omega-3 essential fatty acids</article-title>. <source>Biomed Pharmacother</source><year>2002</year>; <volume>56</volume>: <fpage>365</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">12442909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0753-3322(02)00253-6</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>